Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,446JPY
26 Sep 2017
Change (% chg)

¥0 (+0.03%)
Prev Close
¥1,446
Open
¥1,444
Day's High
¥1,451
Day's Low
¥1,436
Volume
6,946,700
Avg. Vol
7,304,019
52-wk High
¥1,688
52-wk Low
¥1,332

Chart for

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.60
Market Cap(Mil.): ¥2,991,518.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.35

Financials

  Industry Sector
P/E (TTM): -- 31.24 15.93
EPS (TTM): -- -- --
ROI: -- 15.06 14.60
ROE: -- 16.31 13.96

BRIEF-R&I affirms Astellas Pharma's rating at "AA" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I

Sep 20 2017

Pfizer, Astellas prostate cancer drug promising in late-stage trial

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.

Sep 14 2017

CORRECTED-UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial

Sept 14 Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.

Sep 14 2017

Pfizer, Astellas prostate cancer drug clears late-stage trial

Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial.

Sep 14 2017

CORRECTED-Pfizer, Astellas prostate cancer drug clears late-stage trial

Sept 14 Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

Sep 14 2017

BRIEF-Astellas Pharma and Pfizer say positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide)

* Co and Pfizer Inc announced that the Phase 3 PROSPER trial evaluating XTANDI®(enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) CastrationResistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS)

Sep 14 2017

BRIEF-Pfizer, Astellas report positive top-line results from phase 3 PROSPER trial of XTANDI

* Pfizer and Astellas announce positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide) in patients with non-metastatic castration-resistant prostate cancer

Sep 14 2017

BRIEF-U.S. FDA accepts for review Astellas' supplemental NDA for mirabegron for use in combination with solifenacin succinate

* U.S. FDA accepts for review Astellas' supplemental New Drug Application for Mirabegron for use in combination with solifenacin succinate 5 mg for the treatment of overactive bladder

Sep 12 2017

BRIEF-Astellas Pharma submits application for approval of fidaxomicin for the treatment of infectious enteritis in Japan

* Says it has submitted an application for marketing approval of fidaxomicin for the treatment of infectious enteritis in Japan

Jul 31 2017

UPDATE 1-Japanese drugmaker Takeda posts stronger profit as U.S. sales jump

* Astellas Q1 operating profit halves from year ago (Adds wider industry context, Astellas results)

Jul 28 2017

Earnings vs. Estimates